Home/Pipeline/SEL120

SEL120

Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndrome (HR-MDS)

Phase 1bActive

Key Facts

Indication
Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndrome (HR-MDS)
Phase
Phase 1b
Status
Active
Company

About Selvita

Selvita is a key player in the Central and Eastern European life sciences sector, combining a service-based contract research organization (CRO) business with proprietary drug development. The company's core expertise lies in integrated drug discovery, medicinal chemistry, and biology, which it applies to internal oncology programs and external partnerships. Its strategic direction involves advancing its pipeline of small molecule inhibitors while expanding its global CRO footprint. Key achievements include establishing long-term collaborations with major pharmaceutical companies and progressing several proprietary assets into clinical and pre-clinical stages.

View full company profile

About Selvita

Selvita is a key player in the Central and Eastern European life sciences sector, combining a service-based contract research organization (CRO) business with proprietary drug development. The company's core expertise lies in integrated drug discovery, medicinal chemistry, and biology, which it applies to internal oncology programs and external partnerships. Its strategic direction involves advancing its pipeline of small molecule inhibitors while expanding its global CRO footprint. Key achievements include establishing long-term collaborations with major pharmaceutical companies and progressing several proprietary assets into clinical and pre-clinical stages.

View full company profile

Therapeutic Areas